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Abstract: We aimed to develop a mathematical model to predict the progression of aortic stenosis
(AS) and aortic dilatation (AD) in bicuspid aortic valve patients. Bicuspid AS patients who underwent
at least two serial echocardiograms from 2005 to 2017 were enrolled. Mathematical modeling
was undertaken to assess (1) the non-linearity associated with the disease progression and (2) the
importance of first visit echocardiogram in predicting the overall prognosis. Models were trained in
126 patients and validated in an additional cohort of 43 patients. AS was best described by a logistic
function of time. Patients who showed an increase in mean pressure gradient (MPG) at their first visit
relative to baseline (denoted as rapid progressors) showed a significantly faster disease progression
overall. The core model parameter reflecting the rate of disease progression, α, was 0.012/month in
the rapid progressors and 0.0032/month in the slow progressors (p < 0.0001). AD progression was
best described by a simple linear function, with an increment rate of 0.019 mm/month. Validation
of models in a separate prospective cohort yielded comparable R squared statistics for predicted
outcomes. Our novel disease progression model for bicuspid AS significantly increased prediction
power by including subsequent follow-up visit information rather than baseline information alone.
Keywords: bicuspid aortic valve; progression; mathematical model
1. Introduction
Bicuspid aortic valve (BAV) is one of the most common congenital cardiac diseases [1,2]. Prior
studies analyzed the risk of progression of aortic stenosis (AS) or aortic dilatation (AD) in BAV, based
on baseline information, and demonstrated that future surgical intervention was positively correlated
with age and moderate to severe valve dysfunction at baseline [1,3]. In patients with calcific AS, an
association between hypercholesterolemia and AS progression has been reported, suggesting that
progression of AS is similar to that of atherosclerosis [4,5], although prospective trials failed to prove
protective role of statins against AS progression [6–8].
As of yet, no quantitative prediction models of the disease progression trajectories of AS and
AD in BAV have been reported in the literature. Assessing the non-linearity of disease progression
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is necessary to predict the future disease trajectory from serial echocardiographic measurements.
Considering the degenerative nature of AS, the function and morphology of the aortic valve (AV)
would deteriorate rapidly over time with progression of AS. Therefore, including information acquired
from subsequent visits as opposed to baseline factors alone in the analysis may be more appropriate.
In this study, we aimed to answer two specific questions: (1) Can future trajectories of the
progression of AS and AD be linearly extrapolated from a few serial echocardiographic measurements?
If not, what is an effective way to predict the non-linear progression of AS and AD in BAV patients?
(2) Would incorporating the time-varying status of disease into the prediction model improve the
accuracy of individual predictions? By answering these questions, we aim to propose a method to
determine the expected time to reach criteria for intervention for severe AS and AD [3,9,10].
2. Materials and Methods
2.1. Study Population
After excluding patients with significant aortic regurgitation (AR) at baseline or prosthetic valves,
169 bicuspid AS patients with at least two serial echocardiograms were enrolled. Clinical data and
laboratory data at the time of first echocardiogram were obtained. If patients underwent valve surgery
or an interventional procedure during the follow-up period, echocardiographic data obtained just
before the surgery was used to assess the progression of AS. Patients were randomly assigned into the
training group (n = 126) or test group (n = 43) in a ratio of three to one. The AS disease progression
model was derived from the training group of 126 patients, and the model was validated using the test
group of 43 patients. This study was approved by the institutional review board of severance hospital,
Seoul, Korea.
2.2. Echocardiography
All patients underwent two-dimensional transthoracic echocardiography. The first
echocardiography when bicuspid AS was diagnosed was used as baseline. BAV was diagnosed
when only two cusps were unequivocally identified on the short-axis view, with a systolic doming
appearance on the parasternal view [3,11]. The type of BAV was determined based on the presence of
raphe according to previous studies [11,12]. Type 1:1 raphe with a fusion of the left coronary and right
coronary cusps; type 2:1 raphe with a fusion of the right coronary and noncoronary cusps; type 3:1
raphe with a fusion of the left coronary and noncoronary cusps; and type 0:no raphe with 2 developed
cusps. AS assessment was performed according to current guidelines [13,14]. Two-dimensional
ascending aorta measurements were recorded in systole at the sinus of Valsalva (SoV), the sinotubular
junction (STJ), and the proximal ascending aorta (AAo) [15,16]. A follow-up echocardiography was
performed according to clinicians’ decision according to patients’ symptoms and severity of disease.
The median first visit time after baseline measurement was 12.4 months, with 5% and 95% percentiles
of 3 weeks and 48.8 months, respectively.
2.3. Analysis Variables
Variables used for analysis were mean pressure gradient (MPG, mmHg) for AS progression and
the aortic diameters (mm) of SoV, STJ, and AAo for AD progression. Time was expressed in months.
2.4. Aortic Stenosis (AS) Progression Model
2.4.1. Basic Model
Linear and nonlinear models were fitted to serial MPG measurements from the training dataset.
The following models were tested for MPG predictions:
MPG(t) = MPG0 + SL × t (1)
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MPG(t) = MPG0 + (MPG∞ −MPG0) × (1 − exp(α × t)) (2)
MPG(t) =
MPG∞
1 + (MPG∞MPG0 − 1) × exp (−α× t)
(3)
where
MPG0: baseline MPG (= MPG(0))
MPG∞: asymptotic maximum MPG (= MPG(∞))
SL (slope): rate of MPG increment (= ∆MPG/∆t)
α: rate constant of MPG increment.
Equations (1)–(3) will be referred to as linear, asymptotic exponential, and logistic disease
progression models, respectively (Figure 1).
Figure 1. Graphical representation of disease progression model. Mean transaortic pressure gradient
and aortic diameter measurements were used in disease progression modeling for bicuspid aortic
stenosis (AS) and aortic dilatation (AD). Among linear, asymptotic exponential, and logistic models
tested, logistic models best described bicuspid AS progression and a simple linear disease progression
model best described AD progression. MPG—mean pressure gradient.
The linear disease progression model assumes that MPG increases linearly with time. With this
model, predicting the future time course of echocardiographic endpoints would be simple, since the
treating physician could linearly extrapolate from past serial measurements to make future predictions.
On the other hand, if there was significant non-linearity associated with the disease progression, more
elaborate methods would be needed. Asymptotic exponential and logistic progression models assume
that MPG approaches a certain value, MPG∞, with time. The main difference between the two is
in the shape of the disease progression trajectory. The asymptotic exponential disease progression
model assumes that the rate of MPG increment is greatest in the beginning and decreases thereafter.
The logistic disease progression model assumes an S-shaped trajectory of MPG increment, where its rate
is slow in the beginning, becomes faster with time, and then slows again as MPG approaches the upper
bound. For MPG0 in Equations (1)–(3), the observed value was used, with assay error incorporated.
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2.4.2. Incorporation of Information from Subsequent Visits
After selecting the model from Equations (1)–(3) that best describes the data, we investigated
whether subsequent follow-up visit information can be used to improve our predictions. To this end,
an indicator of whether MPG increased from baseline to the first follow-up visit, denoted by λ, was
defined as follows:
λ = MPG′(t1)/MPG0=
MPG(t1) −MPG0
t1 ×MPG0 (4)
In the above equation, t1 is the time of the first visit elapsed since the time of the baseline (t0), and
MPG′(t1) is the derivative of MPG(t) at t1.
Then, assuming that patients can have different values of SL or α (Equations (1)–(3)) depending
on the degree of MPG increment, the following adjustment for predictions were made:
α =
{
θ1 for λ ≤ e
θ2 for λ > e
(5)
In the above, e is the optimal division boundary determined using a grid search algorithm. Values
ranging from 0 to 0.5 with a step size of 0.05 were tested. θ1 and θ2 are SL or α estimated from the
two subgroups. For example, taking Equation (2) as the basic disease progression model, the MPG
trajectories of patients with λ ≤ e would be described as MPG∞
1+( MPG∞MPG0 −1)×exp (−θ1×t)
(see Equation (3)) while
those with λ > e as MPG∞
1+( MPG∞MPG0 −1)×exp (−θ2×t)
. To acquire a good estimate of e, non-linear mixed effects
modeling was undertaken so that random intra-patient variability could be separated from random
inter-patient variability.
2.5. Aortic Dilatation (AD) Progression Model
As was done for MPG, all three disease progression models (linear, asymptotic exponential, and
logistic disease progression models) were tested for SoV, STJ, and AAo or with model formulations
similar to those defined in Equations (1)–(3).
2.6. Model Validation
As stated above, the training dataset consisting of 126 patients was used for model building, and
the test dataset of the remaining 43 patients was used for model validation. The null model was set to
a simple linear model with which other candidate models were compared. Four-fold cross-validation
was performed on the training dataset to ensure that improvements in model fit using the more
complex models (i.e., asymptotic exponential or logistic) were not due to overfitting. Model parameters
were fixed at the values obtained from the training dataset, and adjusted R-squared values were used
to determine how well the model predicted values in the test group. We have chosen R-squared as a
performance metric because ideally, predictions and observations should lie on the line of unity with
minimal scatter (i.e., linear regression of observations on predictions should result in R2 = 1). Moreover,
interconversion between R-squared and mean squared error is possible via the following formula:
1 − R2 =
∑
(observation− prediction)2/N
(observation−mean)2/N =
MSE
Var(y)
(6)
where MSE stands for mean squared error and Var(y) stands for variance of the observations.
2.7. Software
Data exploration, analysis, and simulation were carried out using NONMEM version 7.3
(ICON, https://iconplc.com), PsN version 4.2 (Uppsala university, Sweden, https://uupharmacometrics.
github.io/PsN/), and R version 3.4.2 (https://www.r-project.org/). Categorical variables, expressed in
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percentages or frequencies, were compared using the χ2 test or Fisher’s exact test between rapid and
slow progressors. Continuous variables, expressed in either mean ± standard deviation or median
with range, were compared using Student’s t test between two groups.
3. Results
3.1. Patient Population
The mean observation period was 59.2 months (range, 12–150 months), and the final population
consisted of 169 patients. There were no significant differences based on Student’s t test and χ2 test or
Fisher’s exact test in the clinical and echocardiographic variables of the training group (n = 126) and
validation group (n = 43), except higher estimated glomerular filtration rate, as described in Table S1.
The median age was 61 years (27–86), and 74 patients in the training group (59%) were men. Patients
in the training group had a mean MPG of 27.9 mmHg, and the mean values of SoV, STJ, and AAo were
34.5 mm, 29.4 mm, and 42.0 mm, respectively.
3.2. Disease Progression Model
When linear, asymptotic exponential, and logistic models were tested for the AS progression
model, the logistic model resulted in the highest log-likelihood. Upon four-fold cross-validation, the
difference of objective function value (OFV), defined as the −2 log likelihood of sums of extended
least squares, between logistic and linear disease progression model in the validation datasets was
14.1, with an associated p-value of 0.00017 (see Table S2). Hence, logistic progression model was
selected. Another piece of evidence favoring logistic over linear disease progression model comes from
a two-stage analysis where simple linear regression of MPG on time was carried out on an individual
basis (see Figure S1). The estimated slope coefficient was then stratified on baseline MPG and its
mean values were examined (Table S4). The estimated slope increases from 0.17 mmHg/month, when
baseline MPG is 5–10 mmHg, to 0.26 mmHg/month, when baseline MPG is 20–30 mmHg. In patients
with baseline MPG 30–40, the slope decreases to 0.16 mmHg/month and becomes virtually 0 in patients
with baseline MPG 40–50 mmHg. This suggests that the rate of AS progression is nonlinear and
depends on the MPG value at the time of assessment.
For the AD progression model, neither the asymptotic exponential or the logistic disease
progression model led to a significantly better fit than a simple linear model. Therefore, for SoV, STJ,
and AAo, a simple linear disease progression model would suffice.
3.3. Time to Indication for Intervention
3.3.1. Time to AS Intervention
An MPG of 40 mmHg is considered an indication of severe AS [16]; and, from a therapeutic
perspective, it would be useful to predict the time required for a patient to reach an MPG of 40 mmHg
(T40). Accordingly, T40 was calculated from Equations (1)–(3). For example, T40 for the logistic disease
progression model can be obtained from Equations (2) as follows:
T40= log (
40× (MPG∞ −MPG0)
MPG0 × (MPG∞ − 40) )/α (7)
3.3.2. Time to AD Intervention
Similarly, an aortic diameter of 55 mm is considered a threshold for surgical intervention, [17] and
T55 was predicted based on the selected model. For example, T55 for the linear disease progression
model can be obtained from Equation (1) as follows:
T55 = (55 − D0)/SL (8)
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D0: Diameter of SoV, STJ, or AAo at baseline.
3.4. AS Progression Model
When only baseline information was incorporated, the AS progression model yielded an α
estimate of 0.0091/month in non-type 2 BAV phenotype (type 0, type 1, and type 3) and 0.0045/month
in type 2 BAV (data not shown). No statistically significant difference of the α estimates was found
between types 1 and 3, 1 and 4, or 2 and 4, based on post-hoc ANOVA and multiple Student’s t tests of
the α estimates. The mean individual estimates of α in BAV types 1, 2, 3, and 4 were 0.012, 0.0056,
0.017, and 0.010/month, respectively.
The grid search returned the optimal value of e (see Equation (5)) as 0. The incorporation of first
visit information led to a decrease in AIC (Akaike Information Criteria) that was highly significant
(p < 0.001) compared to the model using baseline data alone. When using this model, there were two
distinct patterns of AS progression that were classified as rapid and slow progressors, as shown in
Table 1.
Table 1. Parameter estimates of the final disease progression model for the training dataset.
Model Type Parameter Population Estimate (%RSE)
Structural Parameter §
MPG α (month−1)
α λ ≤ 0 0.0032 (27.80%)
α λ > 0 0.012 (19.00%)
MPG∞ (mmHg) 95.4 (26.65%)
SoV, STJ, and AAo SL (mm/month) 0.019 (3.62%)
Variance Parameter §§
MPG α (CV%) 72.42 (13.76%)
SoV, STJ, and AscAor SLSoV (CV%) 127.5 (9.29%)
SLSTJ (CV%) 90.4 (12.4%)
SLAscAor 116.6 (8.38%)
§ In the model of SoV, STJ, and AAo, SL was assumed to be the same for all three variables. §§ In the variance
parameter, CV denotes coefficient of variation. %RSE: percent relative standard error, MPG: mean pressure gradient;
SoV, sinus of Valsalva; STJ, sinus tubular junction; AAo, ascending aorta; SL, slope.
Rapid and slow progressors were determined by the rate of MPG change (λ) from baseline to the
first follow-up visit. The estimate of α was 0.012/month for rapid progressors (defined by λ > 0) and
0.0032/month for slow progressors (defined by λ ≤ 0) in the training group. The parameter estimates
acquired from different validation folds during cross-validation procedure are shown in Table S3.
Figure 2 depicts different progression patterns of rapid and slow progressors over time.
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Figure 2. Goodness of fit plots of the AS progression model and T40 predictions for rapid progressors
(λ > 0/month) and slow progressors (λ ≤ 0/month) (training dataset). (A) Goodness of fit plots (dots:
observation, red line: mean observation, blue line: mean prediction with incorporation of subsequent
visit information, green line: mean prediction with only baseline information). (B) T40 predictions for
rapid progressors (λ > 0/month) and slow progressors (λ ≤ 0/month) (training dataset): Rapid and slow
progressor show different T40 predictions (thick lines: means, shaded areas: 50% prediction intervals).
For the simulations, the maximum time was set to 300 months with 0.5 month used as the
time step. To generate 50% prediction intervals, 100 stochastic simulations were performed. The
simulated parameters of each patient were sampled from log-normal distributions centered at the
population mean and the associated variances. For a given baseline MPG (MPG0), the predicted time
to reach MPG of 40 mmHg (T40) was significantly different between slow and rapid progressors. Rapid
progressors yielded a much shorter T40 than slow progressors at all MPG0. This can be observed not
only in mean values, but also in 50% prediction intervals. It can be seen that T40 values decrease with
increasing MPG0.
J. Clin. Med. 2019, 8, 1302 8 of 15
Table 2 compares baseline clinical and echocardiographic characteristics between rapid and slow
progressors. Total cholesterol was marginally higher in rapid progressor compared to slow progressor
(p = 0.061), however, low density lipoprotein (LDL) cholesterol was similar between two groups. Slow
progressors showed a significantly larger left ventricular (LV) end systolic dimension and lower LV
ejection fraction compared to the rapid progressors, but stroke volume was similar in the two groups.
Table 2. Comparison of patient demographics and covariates between rapid and slow progressors.
Characteristics Rapid Progressor (n = 80) Slow Progressor (n = 46) p-Value
Clinical characteristics
Age, year 61 (27–86) 63 (27–82) 0.947
Male gender, (%) 47 (59) 27 (59) 1.000
Body weight, kg 65.3 ± 16.5 62.4 ± 10.2 0.225
Systolic BP, mmHg 123.6 ± 17.3 119.4 ± 17.8 0.195
Diastolic BP, mmHg 77.4 ± 11.8 74.0 ± 13.4 0.150
Hypertension 28 (48) 4 (50) 0.999
Diabetic mellitus 12 (21) 0 (0) 0.333
Dyslipidemia 20 (35) 2 (25) 0.709
Atrial fibrillation 5 (9) 1 (13) 0.555
Prior myocardial infarction 1 (2) 1(13) 0.229
Previous history of stroke 3 (5) 0 (0) 0.999
ACEi/ARB 32 (55) 3 (38) 0.459
Statin 20 (35) 2 (25) 0.709
Calcium channel blockers 11 (19) 2 (25) 0.651
Beta blockers 23 (40) 3 (38) 0.999
Hemoglobin 13.6 ± 2.0 13.4 ± 1.6 0.780
Log NT-proBNP 2.25 ± 0.80 3.28 ± 0.60 0.338
Total cholesterol 179.0 ± 29.7 154.7 ± 29.3 0.061
LDL-cholesterol 104.8 ± 28.1 98.2 ± 20.5 0.578
eGFR 77.8 ± 21.8 78.6 ± 19.0 0.932
Echocardiographic characteristics
LV EDD, mm 51.2 ± 6.9 52.8 ± 9.2 0.292
LV ESD, mm 33.8 ± 6.9 37.5 ± 10.1 0.032
LV mass index, mg/m2 124.1 ± 46.9 136.0 ± 59.5 0.247
LV ejection fraction, % 67 ± 7 57 ± 17 <0.001
LA volume index, ml/ 29.6 ± 15.8 33.2 ± 18.7 0.270
Stroke volume, ml 84.5 ± 21.0 84.1 ± 36.8 0.950
MPG, mmHg 27.3 ± 16.4 29.5 ± 19.3 0.509
AVA, cm2 1.22 ± 0.38 1.21 ± 0.38 0.978
SoV, mm 35.0 ± 5.2 33.6 ± 5.6 0.155
STJ, mm 29.8 ± 5.3 28.9 ± 5.8 0.412
AAo, mm 41.7 ± 5.5 42.4 ± 4.9 0.469
BAV phenotypes
Type I 43 (54) 23 (50) 0.491
Type II 10 (130) 8 (17)
Type III 7 (9) 1 (2)
Type IV 19 (24) 14 (30)
Undetermined 1 (1) 0 (0)
Values were expressed as mean ± SD, median (range) or number (%); BP, blood pressure; ACEi, Angiotensin
converting enzyme inhibitors; ARB, angiotensin receptor blockers; LDL, low density lipoprotein; eGFR, estimated
glomerular filtration rate; LV, left ventricle; EDD, end diastolic dimension; ESD, end systolic dimension; LA, left
atrium; MPG, mean pressure gradient; AVA, aortic valve area; BAV, bicuspid aortic valve; NT-proBNP, N-terminal
pro b-type Natriuretic Peptide.
Figure 3 shows model fits of MPG for individuals with at least three post-baseline measurements,
indicating overall good agreement between observations and predictions, except for individuals with
atypical trends.
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Figure 3. Goodness of fit plots of the AS progression model in selected individuals with at least three
post-baseline measurements (training dataset) (red: observation, blue: prediction).
3.5. AD Progression Model
The rates of increase in the diameter (SL) of SoV, STJ, and AAo did not differ significantly from
each other. Hence, a common SL value was assigned to all three variables, which was estimated to be
0.019 mm/month (Table 1). No significant covariate was found to affect SL. Figure 4 shows goodness of
fit plots for SoV, STJ, and AAo, indicating good agreement between observations and model predictions
for all three variables. Figure 5 shows the model prediction obtained assuming the same baseline for
individuals, visually representing the linear progression of AD with a rate of increment common to all
three variables. Based on this model, the time to surgical threshold (T55) can be derived as follows: T55
= (55 − D0)/0.019. Figure 6 shows goodness of fit plots of these variables in individuals, also indicating
good agreement between observations and model predictions.
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Figure 4. Goodness of fit plots of the AD progression model for sinus of Valsalva (SoV), sinus tubular
junction (STJ), and ascending aorta (AAo); training dataset. (dots: observation, red line: mean
observation, blue line: prediction).
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Figure 5. Model prediction of AD progression obtained assuming the same baseline of 30 mm for SoV
and STJ and 40 mm for AAo for all individuals (training dataset). A common slope (SL) was assumed
for all three variables. Thick lines represent means, and shaded areas represent 50% prediction intervals.
Figure 6. Goodness of fit plots of the AD progression model for SoV, STJ, and AAo in selected individuals
with at least three post-baseline measurements (training dataset) (red: observation, blue: prediction).
J. Clin. Med. 2019, 8, 1302 12 of 15
3.6. Model Validation
Goodness of fit plots for the AS model in the validation group are presented in Figure S2
(population) and Figure S3 (selected individuals). As described in the Methods section, the predicted
curves were obtained using model parameter estimates from the training group. The figure shows
that AS progression in the validation group is reasonably well predicted by the model obtained using
training data when first subsequent visit information is included. This further supports the validity of
the method using λ to predict disease progression in patients with BAV.
The R-squared statistics of the predicted MPG were 0.76 and 0.84 in the training and validation
groups, respectively. R-squared statistics of the predicted SoV, STJ, and AAo were 0.92, 0.93, and 0.82
in the training group and 0.92, 0.90, and 0.88 in the validation group, respectively. These values were
significantly higher than those of the predicted MPG.
4. Discussion
The principal findings of the study are: (1) The disease progression of AS, as opposed to AD, is
non-linear and requires a mathematical model to mimic its trajectory. A logistic time function was
found to describe the overall disease progression reasonably well and enabled a rough prediction of the
future time course at baseline assessment. (2) Incorporation of subsequent follow-up visit information
via the covariate, λ, significantly improved the model predictability for AS compared to using baseline
information only. As a result, two distinctive patterns of AS progression were identified (rapid vs. slow
progressor) when MPG was analyzed, with respect to λ ≤ 0 and λ > 0. The developed model was also
able to predict the time to intervention for the rapid and slow progressor groups for AS and AD. The
results obtained in this study can be used for treatment optimization in BAV patients, including risk
stratification for future intervention, design of appropriate follow-up intervals, and estimation of time
to future intervention for severe AS or AD.
Conventional analysis generally assumes the status of AS to be time invariant and attempts to
predict disease progression by analyzing only baseline characteristics. Several prospective studies
suggested risk factors for AS progression including degree of valve calcification, older age, dyslipidemia,
hypercalcemia, or smoking [18–24]. However, considering the degenerative nature of AS, deterioration
of function and morphology of the AV would accelerate over time with progression of AS. Therefore,
allowing the time course of AS to be time variant would be more appropriate. In this regard, this
study demonstrated a novel, model-based approach to describe the time-varying nature of disease
progression of bicuspid AS and AD.
It should be noted that there were two distinctive phenotypes for AS progression determined
by MPG increment rates during the subsequent follow-up visit. Baseline characteristics of slow
and rapid progressors were similar, except for LV end systolic dimension and LV ejection fraction.
Although the stroke volume index did not differ between the two groups, a higher LV ejection fraction
in the rapid progressor group may suggest increased shear stress of the bicuspid AV. The potential
importance of mechanical stress on calcific AV has been suggested by previous studies similar to
our data [25]. Interestingly, there was no significant difference in lipid profiles and renal function at
baseline between rapid and slow progressors. Rapid MPG increment may reflect overall dynamic
influence of inflammatory or degenerative process of BAV which might not be determined by baseline
information. BAV type did not differ between the rapid and slow progressor groups. Although
progression rate differed according to BAV phenotype when only baseline information was considered,
when subsequent follow-up data were incorporated, types of BAV lost statistical significance.
Interestingly, T40 was significantly shorter in rapid progressors (Figure 2b). This finding is
important because current guidelines do not provide information about how fast AS can worsen or
progress to the threshold for intervention. Previous large cohort studies suggested that older patients
with at least moderate AS severity are likely to experience cardiovascular events, including surgical
AV replacement [1,3]. However, they did not address how long it would take to reach a threshold for
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intervention. The practicality of our suggested AS progression model lies in its ability to predict the
time to reach a surgical threshold for AS.
In our study, we suggested a bicuspid AS progression model based on MPG rather than aortic
valve area (AVA) because accuracy of AVA obtained by measuring multiple echocardiographic variables
can amplify modeling errors. Although AVA has been well validated in both clinical and experimental
studies, MPG is easier and simpler to measure and is accompanied by a smaller measurement
error [26,27]. Therefore, we derived a bicuspid AS progression model based on MPG rather than AVA.
A choice of a binary classification scheme of λ ≤ 0 and λ > 0 is geared more towards clinical utility
than anything else. In fact, a more complex tripartite classification of (i) λ ≤ 0, (ii) 0 < λ ≤ 0.01, and
(iii) λ > 0.01 has shown to lead to better predictability. Here, 0.01 was chosen, since it was the mean λ in
the training dataset, indicating that the choice of 0.01 as the division boundary seems rather arbitrary
since it depends on the mature of the training dataset. While searching for a better classification scheme
would indeed be useful, we have decided to settle with the binary classification scheme, which is
simpler and easier to implement in real clinical situations.
Our suggested AD progression model was described by linear disease progression with a constant
rate of progression. According to our results, the yearly progression rate of aortic dilatation was
0.019 mm/year regardless of baseline aorta size. The progression rate of AD obtained from our study
is significantly lower than the average rate reported in previous studies (1.1 ± 0.15 mm/year), even
after considering the heterogeneity of age and ethnicity of the study population [27,28]. A slower
progression rate in our study may have resulted from our selected study population. Detaint et al. [28]
suggested that rapid progression of AD was observed in younger patients and was related to the
degree of aortic regurgitation (AR). Since our study enrolled BAV patients diagnosed predominantly
with AS, patients with significant AR were excluded. In addition, patients who had a significantly
dilated aorta or an aortic dissection satisfying indications for surgical intervention at diagnosis were
excluded from the analysis because they did not have subsequent follow-up echocardiographic data
prior to the surgery.
A few limitations must be addressed in this study. First, we focused on BAV patients with
predominant AS because assessment of severity is simpler compared to those with AS mixed with
AR. This was also because the indication for undergoing surgical intervention for AS is more objective
than in AR. Further research is required to apply our disease progression model to BAV patients
with significant AR. Second, aortic diameters were measured only by transthoracic echocardiography.
Although echocardiography is the first-choice imaging technique to evaluate the ascending aorta, the
reproducibility for measuring segments of the aorta is limited compared to computed tomography or
magnetic resonance imaging. Considering asymmetric dilatation of the ascending aorta in association
with eccentric blood flow across the AV in BAV patients, measuring the diameter of the ascending
aorta with echocardiography may have limitations. Further study with more reproducible imaging
modality of aorta is needed to assess progression of aortopathy in BAV patients. Third, other imaging
data, such as valve calcification from computed tomography, was not assessed in our study. Although
calcium imaging is an alternative method which offers good prediction of disease progression, repeated
use of CT is limited by cumulative radiation exposures. In addition, serial follow-up of MPG by
echocardiography is currently the recommended method for monitoring hemodynamic progression of
AS. Whether the distribution or burden of valve calcification would differ between rapid and slow
progressor groups needs to be further studied.
5. Conclusions
The novel, longitudinal disease progression model described the time-varying nature of disease
progression of bicuspid AS and AD, and incorporating subsequent follow-up visit data significantly
improved the model predictability for AS. The proposed model can provide useful information
regarding the expected time to reach a threshold for intervention. It is expected that our model will
contribute to tailored management of BAV patients and facilitate risk stratification.
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